FDC Buyback (16 Nov 2026)
FDC Limited announces buyback of up to 24 lakh equity shares for ₹120 crore
FDC · Pharmaceuticals & Biotechnology
Key highlights
- Buyback price fixed at ₹500 per equity share of face value ₹1 each
- Buyback opens November 19, 2026 and closes November 26, 2026
- Buyback size is 4.84% and 4.87% of paid-up share capital and free reserves, per audited FY 2026 financials
Original filing
Letter of Offer
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Engineering Services
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from FDC
- Dividend / buyback / bonusMajor developmentFDC Limited approves results for quarter ended Sep 30, 2026 and share buyback proposal
Other dividend / buyback / bonus filings this fortnight
- Dividend / buyback / bonusKama HoldingsKAMA Holdings approves ₹350 crore buyback of 14 lakh equity shares at ₹2,500 each
- Dividend / buyback / bonusJullundur Motor Agency (Delhi)Jullundur Motor Agency announces buyback of equity shares via tender offer
- Dividend / buyback / bonusDhampur Bio OrganicsDhampur Bio Organics Limited announces ₹50 crore equity shares buyback proposal
- Dividend / buyback / bonusTTK HealthcareTTK Healthcare Limited approves bonus issue of NCRPS to equity shareholders
- Dividend / buyback / bonusAutomobile Corporation Of GoaAutomobile Corporation of Goa completes buyback of 1,44,639 equity shares
- Dividend / buyback / bonusGenus Power InfrastructuresGenus Power Infrastructures Limited completes buyback of equity shares worth ₹148.20 Crores
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.
